Accordingly, the use of a glycolytic inhibitor (2-DG), a glutaminase 1 inhibitor (BPTES) or a c-Myc inhibitor (10058-F4), in addition to regorafenib, effectively inhibited the growth of HCC-PDX tumors with high gankyrin expression36. The gene discussed is PSMD10; the disease is hepatocellular carcinoma.